Profile data is unavailable for this security.
About the company
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
- Revenue in SEK (TTM)4.93m
- Net income in SEK-22.75m
- Incorporated2006
- Employees9.00
- LocationMoberg Pharma AB (publ)Gustavslundsvagen 42, 5 tr.BROMMA 167 51SwedenSWE
- Phone+46 852230700
- Fax+46 87352029
- Websitehttps://www.mobergpharma.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dicot Pharma AB | 233.09k | -50.94m | 299.90m | 3.00 | -- | 10.74 | -- | 1,286.64 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Arctic Bioscience AS | 30.36m | -46.74m | 306.42m | 20.00 | -- | 1.35 | -- | 10.09 | -1.91 | -1.91 | 1.24 | 9.27 | 0.1057 | 0.674 | 2.25 | 1,570,792.00 | -16.27 | -- | -18.44 | -- | 29.20 | -- | -153.95 | -- | 1.21 | -- | 0.0075 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Magle Chemoswed Holding AB | 177.92m | 7.70m | 396.55m | 78.00 | 49.68 | 2.38 | 18.65 | 2.23 | 0.7125 | 0.7125 | 16.47 | 14.84 | 0.628 | 0.5621 | 10.52 | 2,281,000.00 | 2.72 | 2.52 | 3.59 | 3.52 | 87.81 | 85.67 | 4.33 | 3.92 | 0.6117 | 3.42 | 0.3208 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -142.27m | 426.99m | 9.00 | -- | 1.87 | -- | -- | -10.57 | -10.57 | 0.00 | 17.57 | 0.00 | -- | -- | 0.00 | -46.35 | -16.11 | -54.97 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -34.70m | 434.48m | 3.00 | -- | 4.26 | -- | -- | -0.2164 | -0.2164 | 0.00 | 0.6309 | 0.00 | -- | -- | 0.00 | -24.29 | -66.73 | -28.91 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Enzymatica AB (publ) | 44.95m | -55.95m | 441.78m | 17.00 | -- | 4.86 | -- | 9.83 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | -- | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Orexo AB | 615.40m | -96.70m | 485.95m | 112.00 | -- | 19.93 | -- | 0.7897 | -2.81 | -2.81 | 17.86 | 0.7025 | 0.7239 | 1.06 | 2.42 | 5,305,173.00 | -11.38 | -6.41 | -17.08 | -9.99 | 88.22 | 86.76 | -15.71 | -11.83 | 1.51 | -0.5276 | 0.9612 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 525.16m | 23.81m | 530.79m | 45.00 | 22.30 | 2.22 | 13.78 | 1.01 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Moberg Pharma AB (publ) | 4.93m | -22.75m | 555.41m | 9.00 | -- | 0.5723 | -- | 112.68 | -0.9608 | -0.9608 | 0.1936 | 20.27 | 0.0065 | -- | 0.4949 | -- | -3.02 | -- | -3.12 | -- | 65.19 | -- | -461.64 | -- | 12.32 | -- | 0.0043 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| IRLAB Therapeutics AB | 41.59m | -119.45m | 611.11m | 32.00 | -- | 8.78 | -- | 14.70 | -2.30 | -2.30 | 0.8018 | 1.34 | 0.1871 | -- | 0.9707 | 1,599,423.00 | -53.74 | -27.12 | -92.28 | -30.42 | -177.74 | -72.18 | -287.25 | -155.57 | -- | -360.98 | 0.4421 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
Data as of Oct 11 2024. Currency figures normalised to Moberg Pharma AB (publ)'s reporting currency: Swedish Krona SEK
3.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Jul 2024 | 305.03k | 1.07% |
| SEB Investment Management ABas of 28 Jun 2024 | 218.85k | 0.77% |
| FRAM Capital GmbHas of 31 Mar 2024 | 150.00k | 0.53% |
| Skandia Investment Management ABas of 31 May 2024 | 84.11k | 0.30% |
| FCG Fonder ABas of 31 Dec 2023 | 72.16k | 0.25% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 43.21k | 0.15% |
| Skandia Fonder ABas of 31 May 2024 | 1.60k | 0.01% |
More ▼
Data from 29 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
